Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters - 08/12/22

Abstract |
Luteolin and naringenin are flavonoids found in various foods/beverages and present in certain dietary supplements. After a high intake of these flavonoids, their sulfate and glucuronide conjugates reach micromolar concentrations in the bloodstream. Some pharmacokinetic interactions of luteolin and naringenin have been investigated in previous studies; however, only limited data are available in regard to their metabolites. In this study, we aimed to investigate the interactions of the sulfate and glucuronic acid conjugates of luteolin and naringenin with human serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters. Our main findings are as follows: (1) Sulfate conjugates formed more stable complexes with albumin than the parent flavonoids. (2) Luteolin and naringenin conjugates showed no or only weak inhibitory action on the CYP enzymes examined. (3) Certain conjugates of luteolin and naringenin are potent inhibitors of OATP1B1 and/or OATP2B1 enzymes. (4) Conjugated metabolites of luteolin and naringenin may play an important role in the pharmacokinetic interactions of these flavonoids.
Le texte complet de cet article est disponible en PDF.Highlights |
• | PK interactions of luteolin (LUT) and naringenin (NAR) conjugates were tested. |
• | Sulfates showed stronger albumin binding and displacing effects than aglycones. |
• | LUT and NAR conjugates exerted no or weak inhibition on CYP enzymes tested. |
• | The 3‘-sulfate and -glucuronide of LUT were strong inhibitors of OATP1B1. |
• | LUT and NAR conjugates tested were strong inhibitors of OATP2B1. |
Keywords : Luteolin, Naringenin, Sulfate/glucuronide metabolites, Human serum albumin, Cytochrome P450 enzymes, OATP transporters
Plan
Vol 157
Article 114078- janvier 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?